Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics BRAF Mutation Assay

Rosetta Genomics has launched a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. The test uses competitive allele-specific TaqMan (CAST) PCR technology, which can detect as little as 0.5 percent mutated DNA in a large, normal DNA sample. BRAF mutations occur in up to 50 percent of malignant melanomas, and several US Food and Drug Administration-approved BRAF inhibitor therapies have been introduced to the market for use in patients with late-stage metastatic melanoma, Rosetta noted.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.